SMTI

SEC source: 0001493152-21-032041 · ownership.xml · nonDerivative · entry 1

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,020

F1 · shares: Represents shares of common stock of Sanara MedTech, Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 3,546 shares of restricted stock granted to the reporting person on February 24, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

F1 · price: Represents shares of common stock of Sanara MedTech, Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 3,546 shares of restricted stock granted to the reporting person on February 24, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

SEC source: 0001493152-21-032037 · ownership.xml · nonDerivative · entry 4

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,071

F4 · shares: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 801 shares of restricted stock granted to the reporting person on September 30, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

F3 · price: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 802 shares of restricted stock granted to the reporting person on September 30, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

SEC source: 0001493152-21-032037 · ownership.xml · nonDerivative · entry 3

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,267

F3 · shares: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 802 shares of restricted stock granted to the reporting person on September 30, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

F2 · price: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 333 shares of restricted stock granted to the reporting person on April 27, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

SEC source: 0001493152-21-032037 · ownership.xml · nonDerivative · entry 2

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,463

F2 · shares: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 333 shares of restricted stock granted to the reporting person on April 27, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

F2 · price: Represents shares of common stock of the Issuer withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 333 shares of restricted stock granted to the reporting person on April 27, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

SEC source: 0001493152-21-032037 · ownership.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,545

F1 · shares: Represents shares of common stock of Sanara MedTech, Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 503 shares of restricted stock granted to the reporting person on February 24, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

F1 · price: Represents shares of common stock of Sanara MedTech, Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of 503 shares of restricted stock granted to the reporting person on February 24, 2020. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.

SEC source: 0001654954-21-011412 · section16.xml · nonDerivative · entry 1

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,708

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.89 to $34.25, inclusive. The reporting person undertakes to provide to Sanara MedTech Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001654954-21-011258 · section16.xml · nonDerivative · entry 2

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,668

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001654954-21-011258 · section16.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,368

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.32 to $33.56, inclusive. The reporting person undertakes to provide to Sanara MedTech Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001654954-21-010890 · section16.xml · nonDerivative · entry 2

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,708

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.10 to $33.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001654954-21-010890 · section16.xml · nonDerivative · entry 1

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,237

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.07 to $33.01, inclusive. The reporting person undertakes to provide to Sanara MedTech Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001654954-21-010616 · section16.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,668

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.15 to $33.41, inclusive. The reporting person undertakes to provide to Sanara MedTech Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001654954-21-009470 · section16.xml · nonDerivative · entry 1

McMahon Rebecca E · CIK 0001872457 · President of R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,339

F1 · shares: Represents shares of restricted stock granted to the reporting person pursuant to the Sanara MedTech Inc. 2014 Omnibus Long Term Incentive Plan. The shares vest in three equal annual installments beginning on the first anniversary of the date of grant.

SEC source: 0001493152-21-032091 · ownership.xml · nonDerivative · entry 1

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,312

SEC source: 0000897423-20-000097 · edgar.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,668

SEC source: 0000897423-20-000098 · edgar.xml · nonDerivative · entry 2

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,766

SEC source: 0000897423-20-000098 · edgar.xml · nonDerivative · entry 1

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,674

SEC source: 0000897423-20-000096 · edgar.xml · nonDerivative · entry 1

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,708

SEC source: 0000897423-20-000095 · edgar.xml · nonDerivative · entry 1

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,884

SEC source: 0000897423-20-000064 · edgar.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,065

SEC source: 0000897423-20-000059 · edgar.xml · nonDerivative · entry 3

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,065

SEC source: 0000897423-20-000059 · edgar.xml · nonDerivative · entry 2

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,510

SEC source: 0000897423-20-000059 · edgar.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,510

SEC source: 0000897423-20-000058 · edgar.xml · nonDerivative · entry 2

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,105

SEC source: 0000897423-20-000058 · edgar.xml · nonDerivative · entry 1

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,550

SEC source: 0000897423-20-000057 · edgar.xml · nonDerivative · entry 2

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,637

SEC source: 0000897423-20-000057 · edgar.xml · nonDerivative · entry 1

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,540

SEC source: 0000897423-20-000056 · edgar.xml · nonDerivative · entry 1

Thorpe Kenneth E · CIK 0001482846 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,410

SEC source: 0000897423-20-000055 · edgar.xml · nonDerivative · entry 1

HOWELL S ODEN JR · CIK 0001176488 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,394

SEC source: 0000897423-20-000054 · edgar.xml · nonDerivative · entry 1

Salamone Ann Beal · CIK 0001799659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,410

SEC source: 0000897423-20-000053 · edgar.xml · nonDerivative · entry 2

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,249

SEC source: 0000897423-20-000053 · edgar.xml · nonDerivative · entry 1

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

SEC source: 0000897423-20-000052 · edgar.xml · nonDerivative · entry 1

STUCKERT JAMES W · CIK 0001176485 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 822,059

SEC source: 0000897423-20-000051 · edgar.xml · nonDerivative · entry 1

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,229

SEC source: 0001654954-21-010614 · section16.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,065

F1 · balance_after: On February 26, 2020, the reporting person filed a Form 4 (the "Original Form 4") which, among other things, inadvertently reported that the reporting person was awarded 1,000 shares of common stock of Sanara MedTech Inc. (the "Issuer"). The Original Form 4 is hereby being amended solely for the purpose of deleting the second line item that appeared in Table I of the Original Form 4 erroneously reporting that the reporting person was awarded 1,000 shares of common stock of the Issuer and amending Column 5 of the third line item of the Original Form 4 to reflect the actual number of shares beneficially owned by the reporting person following the reported transactions.

SEC source: 0000897423-20-000029 · edgar.xml · nonDerivative · entry 4

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F5 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F5 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000027 · edgar.xml · nonDerivative · entry 2

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 12,049 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F2 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 12,049 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000027 · edgar.xml · nonDerivative · entry 1

Carmena J Michael · CIK 0001732645 · Director · Principal Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,049

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 5,200 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 5,200 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000028 · edgar.xml · nonDerivative · entry 2

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 8,097 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F2 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 8,097 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000028 · edgar.xml · nonDerivative · entry 1

McNeil Michael D. · CIK 0001737969 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,097

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,540 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,540 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000025 · edgar.xml · nonDerivative · entry 1

HOWELL S ODEN JR · CIK 0001176488 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 481,165

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000026 · edgar.xml · nonDerivative · entry 1

Thorpe Kenneth E · CIK 0001482846 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,410 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,410 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000024 · edgar.xml · nonDerivative · entry 1

STUCKERT JAMES W · CIK 0001176485 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 814,830

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 7,229 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000045 · edgar.xml · nonDerivative · entry 3

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 13,555 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F3 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 13,555 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000045 · edgar.xml · nonDerivative · entry 2

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,555

F2 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 1,000 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F2 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 1,000 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000045 · edgar.xml · nonDerivative · entry 1

Bowman Shawn M. · CIK 0001799604 · President - Wound Care Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,555

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 1,510 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 1,510 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000048 · edgar.xml · nonDerivative · entry 2

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 13,555 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F2 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 13,555 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000048 · edgar.xml · nonDerivative · entry 1

Fleming Zachary B. · CIK 0001799602 · President - Surgical Div.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,555

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 4,550 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 4,550 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000044 · edgar.xml · nonDerivative · entry 1

Salamone Ann Beal · CIK 0001799659 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,410 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

F1 · price: On January 7, 2020 the Issuer's Board of Directors approved the grant to the Reporting Person of 2,410 shares of restricted stock to be effective January 21, 2020, subject to specified conditions, but prior to the completion of the grant and the issuance of such shares, the Issuer's Board of Directors, on February 10, 2020, rescinded the grant of all such shares of the restricted stock.

SEC source: 0000897423-20-000029 · edgar.xml · derivative · entry 6

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 179,101 shares

Expires 2021-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

F3 · price: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

F3 · ownership.nature: The 5% Convertible Promissory Note in the principal amount of $1,500,000 was convertible into Common Stock at any time prior to maturity at an initial conversion price of $0.09 per share. As a result a 1-for-100 reverse stock split of the Common Stock on May 10, 2019, the conversion price was automatically adjusted to $9.00 per share in accordance with the terms of the Promissory Note. The terms of the Promissory Note also provided for the right of conversion of any accrued and unpaid interest. The amount of $111,911 in accrued interest was also converted into 12,434 shares of Common Stock at $9.00 per share.

SEC source: 0000897423-20-000029 · edgar.xml · derivative · entry 5

Nixon Ronald T · CIK 0001322573 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,273,630 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · price: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · derivative.exercise_date: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · derivative.expiration_date: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.

F1 · ownership.nature: The Series F Convertible Preferred Stock was convertible into Common Stock at any time on a 2-for-1 basis and had no expiration date. When originally issued the conversion rate was 200-for-1, but on May 10, 2019, as a result of a 1-for-100 reverse stock split of the Common Stock, the conversion rate was automatically adjusted to a conversion rate of 2-for-1 in accordance with the terms of the Series F Convertible Preferred Stock.